- Conditions
- Low-Grade Serous Ovarian Cancer
- Interventions
- Avutometinib, Defactinib, Letrozole
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–34
of 34
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
- Interventions
- Adaptive stereotactic body radiation therapy, Defactinib, Tumor biopsy, Research blood draw
- Device · Drug · Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Low Grade Ovarian Serous Adenocarcinoma, Ovarian Cancer
- Interventions
- avutometinib (VS-6766), avutometinib (VS-6766) and defactinib
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 27
- States / cities
- Scottsdale, Arizona • Santa Barbara, California • New Haven, Connecticut + 23 more
- Conditions
- Epithelial Ovarian Cancer
- Interventions
- Part A - VS-6063, Part A - Avelumab
- Drug
- Lead sponsor
- Verastem, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • Boston, Massachusetts • Oklahoma City, Oklahoma + 2 more
- Conditions
- Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
- Interventions
- Avutometinib, Biopsy, Biospecimen Collection, Computed Tomography, Defactinib, Nivolumab, Positron Emission Tomography
- Drug · Procedure · Biological
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia
- Conditions
- Advanced Colorectal Cancer
- Interventions
- Defactinib, Cetuximab, Avutometinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Cutaneous Melanoma, Brain Metastases
- Interventions
- Defactinib, Avutometinib, Encorafenib
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Salt Lake City, Utah
- Conditions
- Gastric Cancer, Stomach Cancer
- Interventions
- Avutometinib, Defactinib
- Drug
- Lead sponsor
- Ryan H. Moy, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- Defactinib Hydrochloride, Raf/MEK Inhibitor VS-6766, Biopsy
- Drug · Procedure
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Ovarian Cancer
- Interventions
- VS-6063, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Michael McHale
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- San Diego, California